Hi DejaVu

Thanks for that - I had not come across BI 655066 or Stelara before.

Coming back to the NEJM paper. I would have been inclined to split the subjects into four groups (at random and double-blind of course).

Group 1 would get placebo 1 and placebo 2. Group 2 would get guselkumab and placebo 1. Group 3 would get adalimumab and placebo 1. Group 4 would get guselkumab and adalimumab.

The point is that maybe some people with psoriasis will be helped more by both guselkumab and adalimumab (different targets) - Group 4 compared to Groups 2 and 3 - than either in isolation. That could make a difference.

Progressing psoriatic arthritis is not one of my health issues but I hope that you are getting good care .

Kiwi